Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
New survey shows Americans want patent reform
Keytruda Qlex: Where’s the invention?
Two bipartisan bills target patent abuse
Still Overpatented, Still Overpriced
Merck’s Scheme to Product Hop Keytruda
How Celgene and Bristol Myers Squibb Used Volume Restrictions to Delay Revlimid Competition
How Pharma and Its Consultants Abuse the Patent System
We Need More Drug Patent Data
Investigating the pharmaceutical industry’s drug patenting practices
Five Patent Predictions for 2025